Physiomics wins immune-oncology contract from Bicycle Therapeutics

The AIM-traded firm said the project would focus on the mathematical computer modelling of interactions between tumour and Bicycle compounds in an immune-oncology setting.

It said it would be the fourth project it had conducted in the immune-oncology space, with the board saying it highlighted Physiomics’ “rapidly developing” capabilities in an area that was currently receiving “significant” investor and scientific focus.

“We are thrilled to be working with Bicycle Therapeutics, which we believe to be one of the UK's most exciting emerging biotech companies,” said Physiomics chief executive officer Dr Jim Millen.